Document:

Deferred Compensation Plan for Directors

 Exhibit 10.3 
  
 SENETEK PLC 
  
 DEFERRED FEE PLAN FOR DIRECTORS 
  
 Section 1. Purpose. The purpose of the Senetek PLC Deferred Fee Plan (the “Plan”) is to provide non-management directors (the
“Directors”) of Senetek PLC (the “Company”) the opportunity to defer receipt of cash compensation paid by the Company to such persons in their roles as Directors. The Plan is designed to aid the Company in attracting and
retaining as members of its Board of Directors persons whose abilities, experience and judgment can contribute to the well-being of the Company. 
  
 Section 2. Effective Date. The effective date of this Plan is January 1, 2004. 
  
 Section 3. Eligibility. Any Director of the Company who is not deemed to be an employee of the Company or any
subsidiary thereof is eligible to participate in the Plan. 
  
 Section 4. Deferred Compensation Account. An unfunded deferred compensation account (the “Account”) shall be established for each Director who elects to participate in the Plan. 
  
 Section 5. Amount of Deferral. A participant may elect to defer
receipt of all (but not part) of the cash compensation payable to the participant for serving on the Board of Directors or any committee of the Board of Directors of the Company. An amount equal to the compensation deferred, as reflected in the
election referred to in Section 6 hereof, will be credited to the participant’s Account, in the form of phantom Company Ordinary Share units (the “Stock Component”), on the date such compensation would otherwise be initially payable.

  
 Section 6. Time of Election of Deferral. The initial
election to defer compensation under the Plan by persons who are Directors on the effective date thereof shall be made not later than February 28, 2004. Except as set forth herein, thereafter an election to defer compensation shall be made on an
annual basis on or before December 15th of each year on forms approved for that purpose and shall be effective when filed with the Secretary of the Company with respect to all compensation that is paid in the calendar year following the calendar
year in which the election is made. Elections shall be effective when filed with the Secretary of the Company with respect to compensation that is paid in the calendar year following the calendar year in which the election is made (or following
February 28, 2004 in the case of such initial elections). In the case of newly elected Directors who first become eligible to participate in the Plan subsequent to January 1 of any calendar year, such newly eligible participant shall be entitled to
make an election to defer compensation for services to be performed subsequent to the election provided such election is made within 30 days after the date such Director becomes eligible. In this case, such election shall be effective when made with
respect to any compensation to be paid during the period beginning with the date following the date of the election through December 31 of the same initial year of participation. 

 Section 7. Hypothetical Investment. Each Account shall be comprised of the Stock Component and
will be credited on each date compensation is to be paid to Directors and the amount elected to be deferred will be used to credit to the Account phantom units of the Company’s Ordinary Shares (including fractional shares) based upon the fair
market value of American Depositary Shares representing the Company’s Ordinary Shares (“ADSs”) on the date the compensation would otherwise be paid. The Stock Component will be credited on the payment date for any dividend or other
distribution on the Company’s Ordinary Shares with additional phantom Ordinary Share units determined by dividing the aggregate cash dividend or the aggregate fair market value of any other distribution which would have been paid if the
existing phantom Ordinary Share units were actual Company Ordinary Shares by the fair market value of the Company’s Ordinary Shares as of the dividend or other distribution payment date, computed to four decimal places. For purposes of the
Plan, the “fair market value” of one Company Ordinary Share shall be the closing sale price for an ADS on the Nasdaq Stock Market (or such other exchange on which the ADSs may at the time be principally traded) as published in The Wall
Street Journal for the determination date. 
  
 Section 8. Value
of Deferred Compensation Accounts. The value of each participant’s Account at any time shall be equal to the product of multiplying the number of phantom Ordinary Share units representing compensation deferred and dividends and other
distributions credited thereon by the fair market value of one Ordinary Share determined pursuant to Section 7 of the Plan. All deferred amounts to be paid to a participant pursuant to the Plan are to be paid as soon as practicable following the
payment date (as specified below). 
  
 Section 9. Payment of
Deferred Compensation. No withdrawal may be made from the participant’s Account prior to the date specified by the participant in his or her election to defer compensation except as provided in Section 10. At the participant’s
election, deferral of compensation may be made to a specific date, to immediately after the end of the calendar year in which the participant terminates service as a Director, or to the earlier of either one of such dates. Any deferral must be for a
period of at least one year following the year for which the compensation is earned, unless service as a Director terminates earlier. Deferred compensation and dividends or other distributions (including appreciation or loss thereon) will be payable
in whole Ordinary Shares of Senetek PLC plus cash in respect of any fractional Ordinary Share otherwise distributable having a value (determined as provided in Section 7) equal to the value of the Account or portion thereof to be distributed
(determined as provided in Section 8). Distribution shall be in a single installment or in such number of quarterly or annual installments as the participant chooses, subject to the participant’s right to change such method of distribution no
later than twelve months prior to the first date deferred compensation is to be paid. If a participant elects to receive payment from his or her Account in installments, the participant’s Account will continue to accrue dividends and other
distributions (and appreciation or loss) during the installment period. Dividends and other distributions credited to a participant’s Account during the installment period will be paid on the next installment payment date. Any portion of a
participant’s Account attributable to fractional Ordinary Shares of Senetek PLC shall be paid in cash at the same time (or times) as the participant is otherwise paid the amount his or her Account. 

 Notwithstanding the foregoing, if on the date for payment of any portion of a participant’s Account the Compensation
Committee of the Board of Directors determines in its sole discretion that issuance or participant resale of Company Ordinary Shares would be unlawful or not in the best interests of the Company, such payment shall be made in cash in an amount equal
to the value of the Company Ordinary Shares otherwise issuable, determined as provided in Section 8. 
  
 Section 10. Hardship. In the event of a severe financial hardship or unforeseeable emergency, a participant may file a notice with the Secretary of
the Company to be presented to the Compensation Committee of the Board of Directors, advising the Committee of the circumstances of the hardship or emergency, and requesting a withdrawal of previously deferred amounts, or, where a former Director is
receiving annual installment payments, requesting accelerated payment. The Committee, in its sole discretion, may agree to accelerate distribution of all or a part of amounts previously deferred. Should the Committee agree, such distribution shall
occur on a date set by the Committee (the “Hardship Distribution Date”) that is at least six (6) months from the date the Committee approves the hardship withdrawal request. The Committee shall determine, in its sole discretion, how a
current participant’s Stock Component shall be charged for the withdrawal. No member of the Committee may vote on, or otherwise influence a decision of the Committee concerning, his or her request for a hardship withdrawal. A hardship
withdrawal by a participant shall have no effect on any amounts remaining in the participant Account, and shall not have any effect on any current or future deferral election after the hardship withdrawal. 
  
 For purposes of this paragraph, a severe financial hardship or unforeseen
emergency is one resulting from a casualty or other extraordinary and unforeseeable circumstances arising as a result of one or more recent events beyond the participant’s control. To the extent such hardship or emergency is or may be relieved
(i) through reimbursement or compensation by insurance or otherwise, (ii) by liquidation of the participant’s assets, to the extent the liquidation of such assets would not itself cause a financial hardship, and (iii) by cessation of deferrals
under the Plan, accelerated payment may not be made. Withdrawals of amounts because of such a hardship or emergency may only be permitted to the extent reasonably necessary to satisfy the hardship or emergency. Examples of what are not considered to
be such hardships or emergencies include the need to send a participant’s child to college, or the desire to purchase a home. 
  
 Section 11. Change in Control. A “Change in Control” shall mean: (a) a dissolution or liquidation of the Company, (b) a merger or
consolidation in which the Company is not the surviving corporation (other than a merger or consolidation with a wholly-owned subsidiary, a reincorporation of the Company in a different jurisdiction, or other transaction in which there is no
substantial change in the stockholders of the Company or their relative stock holdings), (c) a merger in which the Company is the surviving corporation but after which the stockholders of the Company immediately prior to such merger (other than any
stockholder that merges, or which owns or controls another corporation that merges, with the Company in such merger) cease to own their shares or other equity interest in the Company, (d) the sale of substantially all of the assets of the Company,
or (e) the acquisition, sale, or transfer of more than 50% of the outstanding shares of the Company by tender offer or similar transaction. 

 Notwithstanding any other provision of the Plan, if a Change in Control occurs, then the Company shall
create a trust or take such other actions as are appropriate to protect each participant’s Account. In addition, at the discretion of the acquiring or successor entity in a Change in Control, payments of amounts hereunder made following such
Change in Control may be made in cash or securities of such acquirer or successor (and not in Company Ordinary Shares); provided that the exercise of such discretion shall not reduce the value of a participant’s Account (determined as of the
date a participant receives payment under the Plan) below its value immediately prior to the Change in Control. 
  
 Section 12. Designation of Beneficiary. A participant may designate a beneficiary or beneficiaries which shall be effective upon filing written
notice with the Secretary of the Company on the form provided for that purpose. If no beneficiary is designated, the beneficiary will be the participant’s estate. If more than one beneficiary statement has been filed, the beneficiary or
beneficiaries designated in the statement bearing the most recent date will be deemed the valid beneficiary or beneficiaries. 
  
 Section 13. Death of Participant or Beneficiary. In the event of a participant’s death before he or she has received the full value of his or
her Account, the then current value of the participant’s Account shall be determined as of the day immediately following death and such amount shall be paid to the beneficiary or beneficiaries of the deceased participant as soon as practicable
thereafter. If no designated beneficiary has been named or survives the participant, the beneficiary will be the participant’s estate. 
  
 Section 14. Participant’s Rights Unsecured. The Stock Component credited to each participant Account under the Plan represents merely a
promise of the Company. No property will be transferred pursuant to the Plan except as provided in Section 9, and the Plan shall be unfunded for all purposes. The right of any participant or beneficiary to receive payment under the provisions of the
Plan shall be an unsecured claim against the general assets of the Company, and no provisions contained in the Plan shall be construed to give any participant or beneficiary at any time a security interest in the Account or any other assets of the
Company. 
  
 Section 15. Statement of Account. Statements
will be sent to participants following the end of each year as to the value of their Accounts as of December 31 of such year. 
  
 Section 16. Assignability. No right to receive payments hereunder shall be transferable or assignable by a participant or a beneficiary, except by
will or by the laws of descent and distribution. 
  
 Section 17.
Administration of the Plan. The Plan shall be administered by the Compensation Committee of the Board of Directors of the Company. The Committee shall conclusively interpret the provisions of the Plan and shall make all determinations under
the Plan. The Committee shall act by vote or written consent of a majority of its members. 

 Section 18. Amendment or Termination of Plan. This Plan may at any time or from time to time be
amended, modified or terminated by the Board of Directors of the Company. No amendment, modification or termination shall, without the consent of a participant, adversely affect such participant’s accruals or his or her prior elections.

  
 Section 19. Adjustments. In the event of any change in
the outstanding shares of Common Stock by reason of any stock dividend or split, recapitalization, merger, consolidation, spin-off, reorganization, combination or exchange of shares or other similar corporate change, the Committee will make such
adjustments, if any, as it in its sole discretion deems equitable in the number of shares of Common Stock with respect to which a participant’s phantom Common Stock Units are referenced, such adjustments to be conclusive and binding upon all
parties concerned. 
  
 Section 20. Governing Law. This Plan
shall be governed by and construed in accordance with the laws of the State of California, without regard to the conflicts of law provisions thereof. 

 Senetek PLC  
  
 Deferred Fee Plan for Directors 
  
 Deferral Election Form 
  

Name of Participant:
                                 
  
 Date of Deferral Election:
                                 
  
 Amount of Deferral: all cash director fees 
  
 Payment of Deferred Account (check one): 
  
  ̈ (a) specified date at least one year after end of deferral year:                      
  
  ̈ (b) immediately following calendar year in which Directorship terminates 
  
  ̈ (c) earlier of (a) or (b) 
  
 Form of Payment (check one): 
  
  ̈ (a) single installment 
  
  ̈ (b)              quarterly installments 
  
  ̈ (c)              annual installments 
  
 Beneficiary Name:
                                        
     
  
 Beneficiary Address:
                                        

  
 _________________     
  
 Participant Signature:
                                        

  
 By your signature you accept and agree to be bound by all of the terms of the
Senetek PLC Deferred Fee Plan for Directors as amended from time to time in accordance with the Plan.Settlement Agreement between OMP, Inc. and Senetek PLC

 Exhibit 10.4 
  
 LATHAM & WATKINS LLP 
 Steven M. Bauer (SBN 135067) 
 James L. Day (SBN 197158) 
 505 Montgomery Street, Suite 1900 
 San Francisco, California 94111 
 Telephone: (415) 391-0600 
 Facsimile: (415) 395-8095 
  
 David A. York (SBN 89941) 
 135 Commonwealth Drive 
 Menlo Park, California 94025 
 Telephone: (650) 328-4600 
 Facsimile: (650) 463-2600 
  
 Belinda S. Lee (SBN 199635) 
 633 West Fifth Street, Suite 4000 
 Los Angeles, California 90071-2007 
 Telephone: (213) 485-1234 
 Facsimile: (213) 891-8763 
  
 Kyra G. Busby (SBN 216035) 
 600 West Broadway, Suite 1800 
 San Diego, CA 92101-3375 
 Telephone: (619) 236-1234 
 Facsimile: (619) 696-7419 
  
 Attorneys for Plaintiff 
 SENETEK PLC 
  
 IN THE SUPERIOR
COURT OF THE STATE OF CALIFORNIA 
  
 FOR THE COUNTY OF LOS ANGELES

  

			
	 SENETEK PLC,
  
 Plaintiff,
  
 v.
  
 OMP, INC. (f/k/a Obagi Medical Products, Inc.), and DOES 1 through 10, inclusive,
  
 Defendants.
	 	 CASE NO. BC293829
  
 Assigned To: Hon. J. Stephen Czuleger (Dept. 50)
  
 CONFIDENTIAL SETTLEMENT
 AGREEMENT AND
MUTUAL RELEASE BETWEEN SENETEK PLC AND OMP, INC.

		
	 AND RELATED CROSS-ACTION.
	 	 

 Senetek PLC (“Senetek”) and OMP, Inc. (“OMP”), in full and final settlement of (a)
all claims which have been, or could have been, asserted against each other in the lawsuit captioned Senetek, PLC vs. OMP, Inc. and Does 1-10, Case No. BC293829, now pending in the Superior Court for the State of California, the County of Los
Angeles (the “Pending State Action”), (b) all claims which were, or could have been, asserted against each other in the litigation captioned OMP, Inc. v. Senetek PLC, C 03-4822 VRW (U.S.D.C. for the Northern District of California)
(the “OMP Federal Action”), and (c) all claims which have been, or could have been, asserted by Senetek against Rohto Pharmaceutical Co., Ltd. (“Rohto”) in the case captioned Senetek PLC v. Rohto Pharmaceutical Co., Ltd. C
03-5529 PJH (U.S.D.C. for the Northern District of California) (the “Rohto Action”), hereby enter into the following Settlement Agreement and Mutual Release (“Agreement”). 
  
 1. Within five business days of the execution of this Agreement by Senetek,
OMP shall wire transfer the amount of U.S. $1,500,000.00 to the following account of Senetek PLC: 
  
 WestAmerica Bank 
  
 Account Number 0508-759073 
  
 ABA Number 121140218 
  
 2. For all purposes of this Agreement the following are defined terms: 
  
 a. Territory means the country of Japan; 
  
 b. Authorized Channel of Trade means the sales and distribution channels in which Rohto is currently
distributing that certain product known as Obagi K+, specifically Drug Stores and Variety Stores, including such Drug Stores’ and Variety Stores’ mail-order and Internet sales activities. To be considered in the Territory, mail-order and
Internet sales must be made to “ship to” and billing addresses in the Territory. 
  
 c. Drug Stores are defined as stores specifically licensed to sell over-the counter drugs as more than 50% of their revenue. 

 
 d. Variety Stores are defined as stores that are not
licensed to sell prescription medicines or over-the-counter drugs but are otherwise similar to Drug Stores in terms of the type of products they carry and consumer demographics that they target for appeal. Variety Stores sell many kinds of goods
including cosmetics, accessories and other small household or personal items. Examples of Variety Stores include Loft and Sony Plaza. Variety Stores do not 

 include or encompass upscale “department” stores such as those operated by Matsuzakaya Co., The
Daimaru, Inc., Isetan Co. or Hankyu Department Stores Inc. 
  
 e. Product Unit is defined as a single unit of any skin care product that contains kinetin in a concentration of *** or below as measured by weight, including cosmetic lotions or creams, that (i) is sold by or for
Rohto or OMP in the Territory in the Authorized Channel of Trade, (ii) uses in any manner the name Obagi or any transliteration thereof or any name confusingly similar thereto, and (iii) is manufactured by OMP or Rohto in Japan, or by or for OMP
anywhere in the world. 
  
 3. Beginning with the calendar quarter
commencing April 1, 2004, OMP will make payments in U.S. dollars to the bank account described in paragraph 1, calculated and paid in the following manner: 
  
 a. For each calendar quarter, OMP shall accrue a $*** per Product Unit (as defined above) obligation to Senetek for each Product Unit
sold. 
  
 b. Within sixty days of the end of each
calendar quarter, OMP shall pay the total accrued obligation for the calendar quarter just ended. 
  
 c. When a total of U.S. $500,000.00 has been paid by OMP to Senetek pursuant to this paragraph 3, OMP’s obligation to accrue and make
payments to Senetek shall cease. 
  
 4. So long as OMP shall
remain obligated to make the payments required in paragraph 3 of this Agreement, OMP shall maintain accurate books and records sufficient to show what OMP in good faith believes to be the sales of Product Units in the Authorized Channel of
Distribution in the Territory that are subject to the obligations of OMP set forth above in paragraph 3. The parties agree that OMP’s maintenance of royalty reports from Rohto identifying such sales, on a basis consistent with OMP’s
records of sales by Rohto under that certain Know-How and Trademark License Agreement between OMP and Rohto dated September 13, 2002, shall be sufficient for this purpose. Senetek, upon reasonable notice and terms, shall have the right to audit
these records of OMP to ascertain compliance with paragraph 3 of this Agreement. In this respect, OMP agrees to make the results of any audit of Rohto conducted pursuant to Section 8.3 of that certain Know-How and Trademark License Agreement between
OMP and Rohto dated September 13, 2002 available to Senetek insofar as those results relate to the sales of Product Units. 
  
 5. In consideration of OMP’s payment obligations set forth in paragraphs 1 and 3 of this Agreement, Senetek hereby grants to OMP a non-exclusive
license (with the right to sublicense) to Senetek’s patent and other intellectual property rights to make, have made, import into, offer to sell and sell Product Units in the Authorized Channel of Trade in the Territory. The term of said
license shall be coextensive with the last to 

	***	Confidential treatment has been requested 

 expire of Senetek’s patent rights anywhere in the world (said patent rights to include all existing patents owned by
or assigned to Senetek and any continuations, reissues, or counterparts of those patents). Senetek covenants that it will not assert that OMP, Rohto, their manufacturers, licensees, or customers infringe any patent or other right of Senetek with
respect to OMP’s and Rohto’s manufacture, marketing, or sale of Product Units, including those Product Units sold after OMP’s obligation of accruing and making payments pursuant to paragraph 3 has been satisfied. 
  
 6. Senetek and OMP understand that this Agreement does not license or
authorize OMP or Rohto to manufacture, market or sell kinetin containing skin care products anywhere in the world except with respect to Product Units to be sold in the Authorized Channel of Distribution in the Territory. 
  
 7. Effective as of the full execution of this Agreement, Senetek and OMP, on
behalf of themselves and their predecessors, successors and permitted assigns, and all past and present officers, directors, employees, agents, servants, attorneys and other representatives of any of the foregoing (including persons or entities
controlling, controlled by or under common control with Senetek or OMP), fully, finally, unconditionally, irrevocably and forever release and discharge each other, and each other’s past and present officers, directors, employees, agents,
servants, attorneys, insurers, and other representatives, and all heirs, executors, administrators, predecessors, successors, and permitted assigns of any of the foregoing, from any and all claims, liabilities, causes of action, rights of action and
actions, demands, suits, proceedings, damages, costs, fees and expenses, and any and all claims, demands and liabilities whatsoever, of every name and nature, both at law and in equity, whether known or unknown, suspected or unsuspected
(collectively, “Claims”), which Senetek or OMP has asserted or could have asserted against each other in the Pending State Action and the OMP Federal Action. Notwithstanding anything to the contrary in the preceding sentence, nothing in
this Release shall release Senetek or OMP from any Claim which one party may subsequently have against the other for: (i) breach of this Settlement Agreement; or (ii) any Claim which either party may have for any wrong or breach arising out of any
conduct which occurs after the date of this Release. This release represents a compromise and settlement in full of all claims except those excepted above, whether or not now known, suspected or claimed, which any Party ever had, now has, or claims
to have against another Party, notwithstanding section 1542 of the California Civil Code, which section provides as follows: 
  
 “A GENERAL RELEASE DOES NOT EXTEND TO CLAIMS WHICH THE CREDITOR DOES NOT KNOW OR SUSPECT TO EXIST AT THE TIME OF EXECUTING THE
RELEASE, WHICH IF KNOWN BY HIM MUST HAVE MATERIALLY AFFECTED HIS SETTLEMENT WITH THE DEBTOR.” 
  
 8. Effective as of the full execution of this Agreement, Senetek, on behalf of itself and its predecessors, successors and permitted assigns, and all past
and present officers, directors, employees, agents, servants, attorneys and other representatives of any 

 of the foregoing (including persons or entities controlling, controlled by or under common control with Senetek), fully,
finally, unconditionally, irrevocably and forever releases and discharges Rohto, and its past and present officers, directors, employees, agents, servants, attorneys, insurers, and other representatives, and all heirs, executors, administrators,
predecessors, successors, and permitted assigns of any of the foregoing, from any and all claims, liabilities, causes of action, rights of action and actions, demands, suits, proceedings, damages, costs, fees and expenses, and any and all claims,
demands and liabilities whatsoever, of every name and nature, both at law and in equity, whether known or unknown, suspected or unsuspected (collectively, “Claims”), which Senetek has asserted or could have asserted in the Rohto Action.
Notwithstanding anything to the contrary in the preceding sentence, nothing in this Release shall release Rohto from any Claim which Senetek may subsequently have against Rohto for any Claim which Senetek may have for any wrong or breach arising out
of any conduct which occurs after the date of this Release. This release represents a compromise and settlement in full of all claims except those excepted above, whether or not now known, suspected or claimed, which any Party ever had, now has, or
claims to have against another Party, notwithstanding section 1542 of the California Civil Code, which section provides as follows: 
  
 “A GENERAL RELEASE DOES NOT EXTEND TO CLAIMS WHICH THE CREDITOR DOES NOT KNOW OR SUSPECT TO EXIST AT THE TIME OF EXECUTING THE RELEASE, WHICH IF
KNOWN BY HIM MUST HAVE MATERIALLY AFFECTED HIS SETTLEMENT WITH THE DEBTOR.” 
  
 9. Within five business days of the full execution of this Agreement: 
  
 a. Senetek and OMP will dismiss their claims, with prejudice, in the Pending State Action, each side to bear their own costs and fees; and

  
 b. Senetek will dismiss its claims, with
prejudice, in the Rohto Action. 
  
 10. The parties shall keep the
terms of this Agreement confidential, except that OMP may disclose the terms to Rohto (upon receiving assurances of confidentiality from Rohto), and except as required by law (including and disclosure obligations Senetek may have under U.S.
securities laws). Any public disclosure of the terms of this Agreement shall be approved by both parties, such approval not to be unreasonably withheld. The final decision with respect to a decision to disclose one or more terms of this Agreement
pursuant to U.S. securities laws shall be made by the party bearing the legal obligation of disclosure. 
  
 11. In the dismissal of the Pending State Action, Senetek and OMP shall request that the Court retain jurisdiction over the parties to enforce the
Agreement pursuant to Cal. Civil Proc. Code § 664.6. 

 Dated: March 26, 2004 
  

			
	 By:
	 	 /s/ WADE NICHOLS

	 	 	SENETEK, PLC, by its General Counsel and Executive Vice President, Wade Nichols

  
 Dated: March 26 2004 

 

			
	 By:
	 	 /s/ CURTIS CLUFF

	 	 	OMP, INC., by its Chief Financial Officer, Curtis Cluff

  
 Approved as to Form: 

 
 Dated: March 26, 2004 
  

			
	 LATHAM & WATKINS LLP

		
	 By
	 	 /s/ DAVID YORK

	 	 	 David A. York

	 	 	 Attorneys for Plaintiff SENETEK PLC

  
 Dated: March 26, 2004

  

			
	 DORSEY & WHITNEY LLP

		
	 By:
	 	 /s/ JUAN BASOMBRIO

	 	 	 Juan C. Basombrio

	 	 	 Attorneys for Defendant OMP, Inc.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00066-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00066-of-00352.parquet"}]]